KRAS and non-small cell lung carcinoma: KRAS is one of the most common mutations in non-scale NSCLC and has a high rate in PSC.[77–80] Results from preclinical research on KRAS inhibitors suggest KRAS mutations as a therapeutic target for PSC.[43,74]